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Abstract 
Background: Patient data registries that are FAIR—Findable, Accessible, Interoperable, and Reusable for humans and 
computers—facilitate research across multiple resources. This is particularly relevant to rare diseases, where data often 
are scarce and scattered. Specific research questions can be asked across FAIR rare disease registries and other FAIR 
resources without physically combining the data. Further, FAIR implies well-defined, transparent access conditions, 
which supports making sensitive data as open as possible and as closed as necessary.
Results: We successfully developed and implemented a process of making a rare disease registry for vascular anoma-
lies FAIR from its conception—de novo. Here, we describe the five phases of this process in detail: (i) pre-FAIRification, 
(ii) facilitating FAIRification, (iii) data collection, (iv) generating FAIR data in real-time, and (v) using FAIR data. This 
includes the creation of an electronic case report form and a semantic data model of the elements to be collected (in 
this case: the “Set of Common Data Elements for Rare Disease Registration” released by the European Commission), 
and the technical implementation of automatic, real-time data FAIRification in an Electronic Data Capture system. 
Further, we describe how we contribute to the four facets of FAIR, and how our FAIRification process can be reused by 
other registries.
Conclusions: In conclusion, a detailed de novo FAIRification process of a registry for vascular anomalies is described. 
To a large extent, the process may be reused by other rare disease registries, and we envision this work to be a sub-
stantial contribution to an ecosystem of FAIR rare disease resources.
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Background
Rare disease (RD) registries contain valuable informa-
tion for improving diagnosis, treatment and event pre-
vention [1]. For this reason, extensive research has been 
performed on setting up high quality and effective RD 
registries [2, 3]. Using this information for research gen-
erally requires data from more than one registry, due to 
the low prevalence of RDs. However, RD registries are 
distributed across the world. Also, data from these regis-
tries are available in heterogeneous formats and multiple 
languages. As a consequence, optimising the use of RD 
registries for research requires substantial effort, and is 
further complicated by legal constraints and the need for 
proper precautions for protecting the privacy of the sen-
sitive data. Kodra et al. [2] and Rubinstein et al. [4] men-
tion the FAIR data principles as a means to make the use 
of distributed RD data as effective as possible.
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The FAIR data principles aim to enable efficient analy-
sis of data across multiple sources through enhancing 
their Findability, Accessibility, Interoperability and Reus-
ability for humans and computers [5]. Data that are FAIR 
at their source are prepared for efficient computational 
analysis across multiple FAIR sources. For instance, 
multiple FAIR sources can be queried simultaneously to 
answer a research question in so-called ‘federated que-
ries’ that do not require source data to be moved to one 
central location [6]. FAIR data are not open by definition. 
FAIR implies well-defined, transparent access conditions, 
which supports making data as open as possible and as 
closed as necessary [7]. By applying the FAIR principles 
to RD registries (here referred to as the data collected 
from RD patients), analysis across multiple RD registries 
and other relevant FAIR data is made possible, even when 
access criteria differ per source.
The added value of the FAIR principles for RD research 
led to early acknowledgement by the RD community, 
and in 2017 the FAIR principles became a recognised 
resource by the International Rare Disease Research 
Consortium (IRDiRC) [8]. For example, since 2014, 
“Bring Your Own Data” workshops (BYODs) have been 
held to accelerate the adoption of the FAIR principles [9–
11]. This includes a series of annually recurring BYODs 
in the RD domain. Over the years, the FAIRification pro-
cess applied in BYODs has been explored and refined, 
and finally described step-by-step in a generic workflow 
[12]. Other research communities have also developed 
similar workflows, such as the workflow for FAIRifica-
tion of data for health research by Sinaci et  al. [13]. An 
important step of this FAIRification process is to make 
data interoperable and machine-readable in a format that 
can be read and processed by computers. Data and data 
access protocols can be made machine-readable by anno-
tating and structuring them with ontologies, which also 
ensures that data may be more easily analysed across RD 
registries using federated queries. IRDiRC has recognised 
ontologies to describe e.g. phenotypes (Human Pheno-
type Ontology—HPO [14]) and rare diseases (Orphanet 
Ontology for Rare Disease—ORDO [15]).
Another effort to further improve research across 
RD registries is the "Set of Common Data Elements for 
Rare Diseases Registration" (CDEs) released by the Joint 
Research Centre of the European Commission [16]. The 
set consists of 16 data elements that are considered to be 
essential for research. Next to this, the European Com-
mission has set up the European Rare Disease Registry 
Infrastructure (ERDRI) to facilitate findability of RD reg-
istries [17], an important task for the European Reference 
Networks (ERNs) [18]. The ERNs are virtual networks 
at a European level, involving healthcare institutes rec-
ognised as expert centres for specific RDs. ERNs aim to 
facilitate discussion on complex or rare diseases and con-
ditions that require highly specialised treatment. Also, 
they aim to concentrate knowledge and resources. To 
that end, ERNs have been provided funding to set up reg-
istries [19]. Minimum requirements include support for 
the CDEs, linking registries and making them interoper-
able. The European Joint Programme on Rare Diseases 
(EJP RD) further supports registries in implementing 
the FAIR principles. VASCERN is the ERN focusing on 
rare multisystemic vascular diseases [20]. VASCERN is 
subdivided into thematic working groups, one of which 
is the Vascular Anomalies working group, VASCA [21]. 
VASCA includes nine centres with individual databases 
and data collection processes.
Here, we describe how we set up a FAIR registry for 
vascular anomalies (hereafter referred to as the VASCA 
registry) in one of the VASCA centres, Radboud univer-
sity medical center. The objectives were to (1) base our 
VASCA registry on the CDEs and the FAIR principles to 
enable it for analysis across RD registries, and (2) imple-
ment de novo FAIRification in our VASCA registry, 
where data are made FAIR automatically and in real-time 
upon collection. By doing all the hands-on work for the 
FAIRification before data collection, data is made FAIR 
through entering them into an Electronic Data Cap-
ture (EDC) system. This mitigates the need for post-hoc 
FAIRification operations, which include repeated, semi-
manual conversions of the data collected into machine-
readable data that is performed after data collection. 
The de novo approach saves time and budget for the 
actual FAIRification of the data in the VASCA regis-
try. To our knowledge, this is the first attempt to create 
a de novo FAIR RD registry, and may therefore serve as 
an example for (and be reused by) other registries. This 
article focuses on the FAIR part of the registry and not 
on setting up a registry in general (for recommendations 
for setting up effective and high quality RD registries in 
general see for example Kodra et al. [2] and Stanimirovic 
et  al. [3]). Therefore, this article describes the complete 
de novo FAIRification workflow, from identifying FAIRi-
fication objectives and required expertise to querying 
data over a FAIR Data Point. The technical implementa-
tion in the EDC system is described in detail in Kersloot 
et al. [22].
Results
We present a workflow for the de novo FAIRification 
process of the VASCA registry (Fig. 1, see Methods and 
Additional file 1: Supplementary Methods). In the follow-
ing sections, we describe how our approach contributes 
to each of the four facets of FAIR as well as how it can be 
reused by other RD registries. For an automated assess-
ment on the FAIRness [23] of our output, the FAIRified 
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data and metadata, using the FAIR Evaluation Services 
[24] see [22].
Contribution to the four facets of FAIR
Contribution to F—Findable
We made the VASCA registry findable in searches for 
humans and computers by providing a description of 
the registry data (‘metadata’) relating to findability. The 
metadata was structured and made machine-readable 
using the Data Catalog Vocabulary (DCAT) standard (see 
details in Additional file  1: Supplementary Methods—
step 8). Each vocabulary term in the DCAT standard 
has a globally unique identifier with a machine-readable 
definition that can be found on the internet. The DCAT 
standard provides terms to denote metadata that facili-
tates findability such as: database title (‘Registry of Vas-
cular Anomalies’), description (‘Databases of the ERN 
vascular anomalies’), and country (‘The Netherlands’). 
The metadata was made available in a FAIR Data Point 
[25, 26] and represented for humans in a visual interface 
and for computers in the Resource Description Frame-
work (RDF) [27]: http:// purl. org/ castor/ fdp/ catal og/ 
vasca. Note that finding the VASCA FAIR Data Point 
does not necessarily mean that the registry data can be 
accessed, interoperated and reused. This is covered in the 
following sections.
VASCA registry metadata was also made findable for 
humans in the European Directory of Registries (ERDRI.
dor) [28] under the namespace: “European Rare Vascular 
Anomalies Registry”. Metadata in ERDRI.dor include the 
medical areas involved, rare diseases registered, charac-
terisation of the registry, and affiliation to the ERN. At 
this time the metadata registered in ERDRI.dor is not yet 
findable for computers in a FAIR format such as DCAT.
Contribution to A—Accessible
We made the VASCA registry accessible by providing 
metadata in the VASCA FAIR Data Point that describes 
the access protocols for the registry data in the DCAT 
vocabulary’s ‘distribution’ component within the FAIR 
Data Point record. Access protocols define where 
requests for access (calls) are sent and under which con-
ditions a call will be accepted in order to gain access to 
data. In addition, calls will generally contain a payload 
that follows a particular interface format in order to be 
interpreted by the data endpoint. We accept the HTTP 
protocol for calls to the data endpoint and accept two 
interface formats—SPARQL Protocol and RDF Query 
Language (SPARQL) via HTTP GET, and simple HTTP 
GET. SPARQL allows for the execution of queries on data 
that is made available in RDF (similar to SQL for data 
in relational databases) and can also be used for feder-
ated querying across multiple data sources. To retrieve 
data, SPARQL queries use the semantic data model and 
ontologies that describe the data (see Additional file  1: 
Supplementary Methods and Figure S2). Another access 
protocol was included for simple retrieval, to support 
viewing or exporting the machine-readable data and 
can, for example, be used to perform analyses on a local 
computer.
Access to the VASCA registry data is managed by the 
authentication and authorisation system of the EDC sys-
tem (see Additional file  1: Supplementary Methods—
step 14). Access can be granted to users (currently only 
humans) by the VASCA registry contact person specified 
in the metadata in compliance with the informed consent 
(see Additional file 1: Supplementary Methods—step 9). 
Note, the ‘Reusability’ facet also relates to the access of 
registry data and metadata, but focuses on permission 
and trust, such as consent, license, and attribution.
Contribution to I—Interoperable
We made the VASCA registry machine-readable and 
interoperable at a number of levels. First, the metadata 
was structured using the DCAT vocabulary following 
the FAIR Data Point specification. This contributes to 
machines being able to query the existence of the registry 
and its content descriptions. Second, the registry patient 
data collected in the eCRF was structured using a seman-
tic data model [29] constructed from terms and relations 
in commonly used ontologies (e.g. SNOMED CT and the 
IRDiRC recognised ontologies HPO and ORDO). Third, 
the VASCA registry was configured to collect data for 
the CDEs, and descriptions of these data elements were 
registered in the ERDRI Metadata Repository (ERDRI.
mdr) [30] under the namespace:’European Rare Vascular 
Anomalies Registry’. The CDEs do not directly address 
any FAIR interoperability principles but do increase the 
compatibility of data in registries for certain analyses. 
Using an ontological model to define the meaning of 
these data elements ensures that we give access to a har-
monised set of data elements and facilitate integration 
(See figure on next page.)
Fig. 1 Workflow of the de novo FAIRification process of a registry for vascular anomalies. The workflow is divided into five ‘phases’: pre-FAIRification, 
facilitating FAIRification, data collection, generating FAIR data in real-time, and using FAIR data. The phases are further specified by ‘steps’ indicating 
practical FAIRification tasks. Abbreviations: electronic Case Report Form (eCRF), Electronic Data Capture (EDC), Resource Description Framework 
(RDF; machine-readable language), FAIR Data Point (FDP)
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Fig. 1 (See legend on previous page.)
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of CDEs from different registries, even across different 
ERNs. We note that without such an ontological model, 
computers cannot assess that common data elements are 
indeed common.
Contribution to R—Reusable
We made the VASCA registry reusable for humans and 
computers by providing metadata in the VASCA FAIR 
Data Point relating to reusability. Each metadata layer 
contains references to a license, the publisher (organisa-
tion and person), media type, version, and timestamp of 
the underlying data or metadata. More metadata is stored 
in the ERDRI.dor overview, but at this time this informa-
tion can only be accessed after logging into the EU RD 
platform and is not yet accessible in a FAIR format. The 
VASCA registry collects clinical data, which contains pri-
vacy sensitive data. By making it FAIR, the registry data 
is as closed as necessary and as open as possible for other 
researchers (humans) and computers. The metadata in 
the VASCA FAIR Data Point is open with a CC0 license 
[31], whereas, the patient-derived data in the VASCA 
registry is only accessible to researchers that have been 
granted access by the registry contact person (see ‘Acces-
sibility’ facet).
The metadata in the VASCA FAIR Data Point contains 
a reference to an RDF ‘distribution’ of the data that can be 
queried in terms of the CDE semantic model (see Addi-
tional file 1: Supplementary Methods and Figure S2). An 
example ontological query could be: “List all phenotypes 
reported for patients diagnosed with any type of vascu-
lar anomaly or angioma from VASCA FAIR Data Points 
in France, Germany, and The Netherlands”. These queries 
can span multiple databases, as ontologies are not bound 
to a single dataset, thereby enabling federated querying.
Reusability of the de novo FAIRification process
Several aspects of the de novo FAIRification process of 
the VASCA registry have been made available and can be 
reused by ERNs for setting up their FAIR RD registries 
that collect the CDEs. The workflow (Fig. 1) and exper-
tise (Additional file 1: Table S1) used in our FAIRification 
projects can be reused for organisation and preparation 
of other projects. Likewise, other aspects developed for 
our project that can be reused are our interpretations, 
semantic data model, and eCRF of the CDEs, FAIR 
implementations in the EDC system, and structured 
metadata describing the VASCA registry.
We interpreted the CDEs in order to define what 
data should be collected in the registry (Additional 
file  1: Supplementary Methods—step 2). In our opin-
ion the CDEs are multi-interpretable, hence, down-
stream implementations depend on these. We therefore 
properly defined and made our interpretations reus-
able for others in an extensive manual (available upon 
request).
We created a semantic data model that describes 
the CDEs and their relation, and made it available on 
GitHub [29] (Additional file  1: Supplementary Meth-
ods—step 5). Efforts to further develop and maintain 
the model are taking place [32] (also see Discussion). 
The goal of sharing the model is twofold: (1) Reuse: 
other ERNs can directly implement the model and 
would only need to extend the model with elements 
that are not a part of the CDEs; (2) Improving interop-
erability: It is easier to perform analyses across datasets 
if they use the same semantic model (using different 
models requires ontology mapping to facilitate feder-
ated querying).
Castor EDC [33], the vendor of the EDC system used 
in our project, developed the technology to facilitate 
the de novo FAIRification of the VASCA registry (phase 
ii in Fig. 1). The eCRF designed for the CDEs, including 
the technology to translate to machine-readable format, 
are reusable (Additional file  1: Supplementary Meth-
ods—steps 6 and 7). The eCRF can be copied directly 
to a new database within the EDC system, to initiate a 
new ERN registry. Some ERN-specific adaptations may 
be necessary. For instance, diagnosis is registered using 
a drop-down menu focusing on vascular anomalies and 
should therefore be adjusted for an ERN with a differ-
ent focus. The ontologies used in the CDE semantic 
data model are not limited to an area of disease. The 
developed (eCRF to RDF) data transformation applica-
tion (Additional file  1: Supplementary Methods—step 
6 onwards; [17]) is generic and can be reused by other 
registries and clinical trials, ensuring that new FAIRifi-
cation projects can easily be set up within the EDC sys-
tem. Likewise, other registries in the EDC system can 
reuse the FAIR Data Point structure and query func-
tionalities developed for the VASCA registry (Addi-
tional file  1: Supplementary Methods—steps 8, 12, 
13, 14, and 15). Furthermore, we have made our eCRF 
interoperable and reusable, as the codebook describ-
ing the eCRF templates containing the CDEs and the 
ontologies to annotate them is openly available in ART-
DECOR [34]. Via the openly available iCRF Generator 
tool [35], the codebook can be directly implemented in 
other EDC systems such as OpenClinica and REDcap.
Finally, structured metadata describing the VASCA 
registry on ERDRI.mdr and the FAIR Data Point are reus-
able. Structured record level metadata of the CDEs were 
included in ERDRI.mdr (name and descriptions of data 
collected for the CDEs). Other registries can clone and 
reuse the VASCA ERDRI.mdr metadata if they are set-
ting up a registry according to the CDEs.
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Discussion
This project aimed to (1) base our VASCA registry on the 
CDEs and FAIR principles to enable it for analysis across 
RD registries, and (2) implement de novo FAIRification 
in our VASCA registry, where data are made FAIR auto-
matically and in real-time upon collection. With regard 
to this first objective, we created an ontology-based 
semantic model of the CDEs recognised by the Euro-
pean RD community and implemented this model in our 
eCRF. As a result, machine-readable data can be queried 
through a FAIR Data Point, thereby facilitating analysis 
across RD registries. Within this project, we opted for 
a de novo approach (objective 2). To this end, we devel-
oped software that converts ‘normal data’ entered in the 
eCRF automatically into machine-readable data, thereby 
following the semantic model implemented. This comes 
with the great advantage, that data is made FAIR and 
available for research upon data entry as well as that clin-
ical people are not tasked with the technical data conver-
sion steps.
The step-by-step description provided in this paper, 
might help other ERNs and RD stakeholders setting up 
their own FAIR registries. In the following sections, we 
discuss the lessons we learned during the project and 
describe our ideas for future developments.
Lessons learned
The interpretation and collection of the Common Data 
Elements
The CDEs include seemingly simple elements that turned 
out to be multi-interpretable. As an example, ‘sex’ can be 
interpreted as both genotypic sex and declared sex. Or, 
the element ‘date of first contact with a specialised centre’ 
requires a clear definition of a specialised centre; should 
it be a Healthcare Provider (HCP) that is a full ERN 
member, or can it also be an expert unit not being part 
of the ERN yet? In order to use a registry for research 
it is essential that it is clearly defined how the CDEs are 
interpreted for each registry to avoid the possibly false 
assumption that they are interpreted uniformly across 
registries. We recommend that all registries clearly docu-
ment their interpretations of the CDEs, for instance in a 
manual such as the one created for our VASCA registry. 
Ideally, guidelines are provided on a European level.
Another issue regarding the CDEs is the discrepancy 
between data to be collected for the registry and data 
that is actually collected within the Electronic Health 
Record (EHR) in daily clinical practise. For example, 
the ORPHAcodes used to define the diagnosis are very 
extensive and include a hierarchy. In clinical practice, 
clinicians may not use ORPHAcodes to code diagno-
ses in a patient’s medical record, nor use these detailed 
categories. Another example is the CDE ‘disability’. The 
EU prescribes to operationalize the CDE ‘disability’ using 
the WHO Disability Assessment Schedule (WHODAS). 
WHODAS, however, is only validated for adults, whereas 
a significant part of patients suffering from rare diseases 
are children.
Furthermore, the CDEs form a static description, 
thereby not capturing changes in the patients’ situation 
over time (follow-up). The data collected for the CDEs 
only represent their situation at the moment of data cap-
ture, but for some CDEs changes over time are likely to 
happen. For example, the execution of (new) diagnostic 
tests in a specialised centre or starting (new) treatments 
might very well affect the outcome of the disability score. 
Also, over time, new test results might become avail-
able (e.g. genetic tests, imaging), affecting the diagno-
sis. It is currently unclear in what cases and within what 
timeframe the information for already included patients 
should be updated. To this end, advice and alignment on 
when to assess and update the CDE data is needed.
The 16 CDEs form the core of the registries, but based 
on discussions with clinicians across Europe, we con-
cluded that clinicians wish to extend the dataset with dis-
ease-specific elements that most probably differ between 
registries. This is, however, something that affects the 
work required for FAIRification, as the semantic data 
model should be extended with these disease-specific 
elements. Consequently, guidelines are required for 
extending the core CDE model with disease-specific ele-
ments. Also, coordination on data modelling is required 
between ERNs and/or registries to ensure compatible 
solutions (see also next section).
The semantic data model of the Common Data Elements
We learned that selecting ontologies can be difficult, as 
this process depends on the interpretation of the CDEs. 
When a CDE is interpreted similarly in different projects, 
it is recommended that the same ontology is used, as this 
prevents the need for mapping between ontologies. To 
this end, we recommend that a standard set of ontologies 
should be defined for ERN registries (in addition to HPO 
and ORDO) to enhance interoperability. When a CDE 
is interpreted differently in different projects, correct 
interpretation by FAIR should be facilitated: differences 
in interpretation are acceptable as long as these interpre-
tations are explicit and represented in both human- and 
machine-readable formats.
In the current project, interpreting the CDEs and 
selecting the corresponding ontologies were handled as 
two distinct activities and to some degree performed sep-
arately and independently. As shown in Additional file 1: 
Table S1, different expertises were required for interpre-
tation of the data elements (clinicians specialised in and 
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patient advocate for vascular anomalies) and generat-
ing a semantic data model (local and FAIR data steward, 
semantic data modelling specialist and clinicians special-
ised in vascular anomalies). To enhance efficiency and 
quality of the semantic data model, we recommend both 
expertise to be at the table when developing and discuss-
ing the semantic data model (at least in the conceptual 
modelling part).
During our FAIRification project, as expected, the 
semantic data model continued to evolve. We docu-
mented and implemented the first complete version of 
the model. Currently, the model is being further devel-
oped and optimised by ontology experts in EJP RD. 
Besides this, in future we foresee ongoing adjustments 
due to e.g. improvement of technologies, ontologies, as 
well as changes to the CDEs themselves. The question is 
if, how, and to what extent this would affect the interop-
erability of datasets. Therefore, one should think of how 
the community should deal with the use of different mod-
els (versions). Researchers should be able to use different 
versions of the model. Therefore, mapping between ver-
sions is essential. We foresee different approaches to deal 
with this. One would be that the ‘owner’ of the registry 
adjusts to a new model or new version. Another approach 
would be that newly developed models or versions are 
made mappable to earlier versions, meaning that the 
community should be provided with either mapping 
tools or mappable models when the CDE-based seman-
tic data model is further optimised. We would argue that 
the latter approach would be preferred as it requires less 
effort of the end users. Particularly if many research-
ers (end users) make use of the same model, this second 
approach is beneficial, as the modelling work only needs 
to be done once. In contrast, in the first approach all 
users would need to adjust to the model individually. Fur-
ther optimisation of the model also leads to further com-
plexities such as different versions of semantic models 
needing to be mapped to different versions of the eCRF. 
In both approaches, our de novo FAIRification frame-
work implies less extra work when a model is changed 
compared to post-hoc FAIRification. The conversion into 
a machine-readable format is more or less automatic and 
would only require implementing the updated model in 
the eCRF (Methods step 6). In contrast, post-hoc FAIRifi-
cation would require additional redoing the semi-manual 
conversion into a machine-readable format.
FAIR implementation in the EDC system
Enabling de novo FAIRification in the Castor EDC sys-
tem required developing the necessary technology from 
scratch. We first piloted the generation of machine-
readable data to test the integration between the data 
transformation application and the EDC system. We 
prioritised developing a generic tool, rather than a 
smaller registry-specific tool, as it can be used by a large 
number of registries and clinical studies. The scalability 
of our approach contributes to making more FAIR data 
available for the community.
In addition, we decided to implement authentication 
and authorisation layers in the FAIR Data Point by reus-
ing the authentication and authorisation of the EDC sys-
tem. This means that at the moment, researchers that do 
not have access to the database in the EDC system are 
not able to access the data through the FAIR Data Point.
Informed consent
Informed consent is usually required for collecting pro-
spective patient data for scientific purposes. The Euro-
pean Commission has provided the ERNs with a standard 
patient information folder (PIF) and broad informed con-
sent form (ICF). Our Institutional Ethical Review Board 
did not approve the PIF and ICF for scientific registries. 
Main reasons were that the information provided on data 
handling was too limited. Therefore, our Institutional 
Ethical Review Board requested us to redraw the PIFs 
and ICFs. This has several possible consequences. Not 
only do the different centres need to follow local guide-
lines, one also needs to make sure data exchange is facili-
tated in an easy way. Future collaborations including data 
sharing with other parties and the own ERN working 
group should explicitly be part of the PIFs and ICFs.
Preconditions for an effective (FAIR) registry
Previous research has investigated the preconditions for 
the establishment of a RD registry. Using focus group 
sessions, Stanimirovic et al. [3] identified that the effec-
tive development of a national RD registry, followed by 
the establishment of a RD ecosystem, requires a broad 
approach that entails a whole series of systemic changes 
and considerations. Moreover, well-orchestrated and 
well-funded efforts to achieve this goal should involve 
coordinated action of all stakeholders, including a regu-
latory framework, quality design, and enactment of a 
general RD policy, as well as the alignment of medical, 
organizational, and technological aspects in accord-
ance with the long-term public healthcare objectives. 
Most of these aspects are also identified by Kodra et al. 
[2]. All these prerequisites are also essential for setting 
up effective FAIR registries. Adding the FAIR aspects to 
a registry, puts extra ‘pressure’ on several of these pre-
conditions. First, additional demands are made on the IT 
infrastructure, as it should also facilitate the conversion 
of clinical data into ontological (meta)data and feder-
ated querying via FAIR Data Points. In case of the latter, 
the FAIR Data Points should be able to connect differ-
ent (types of ) registries. These additional demands on IT 
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infrastructure apply to both development or setting up of 
the registry and long-term maintenance of the registry. 
Secondly, the legal basis might be more complex, as there 
should not only be a legal basis for collecting data, but 
also for (automated) sharing and re-using data (by oth-
ers). In case others aim to re-use the data via SPARQL 
queries in the FAIR Data Point, one should determine if 
the nature of the query and purpose for which the query 
results will be used, match the original legal basis of the 
registry. Ideally, these aspects are checked automatically 
in the FAIR Data Point. This technology is yet to be devel-
oped. Furthermore, FAIR data stewards, semantic model-
ling specialists, interoperability experts, and experts on 
standards for automated access protocols and privacy 
preservation should be added to the already highly inter-
disciplinary group of professionals tasked with setting up 
the registry.
Future developments
The rapid development of FAIR technologies and possi-
bilities requires us to continuously improve our FAIRi-
fication workflow. We are currently working on several 
aspects, discussed below.
The European Patient Identity Management (EUPID) 
pseudonymization tool [36] is recommended by the 
European Commission [37] and aims to ensure that dif-
ferent registries can be mapped on a patient-to-patient 
level. However, at the time of setting up the VASCA reg-
istry, EUPID was not up and running yet and, therefore, 
not implemented in the VASCA registry. We are cur-
rently exploring the technical options to integrate EUPID 
into the registry, taking aspects related to automation, 
security, privacy and efficacy into account.
As described in Additional file 1: Supplementary Meth-
ods, we mapped the International Society for the Study of 
Vascular Anomalies (ISSVA) terms to the ORPHAcodes. 
However, the ISSVA terms not present in ORDO lacked 
a unique identifier. To comply with the interoperabil-
ity principles, we are currently transforming the ISSVA 
classification into an ontology (OWL format), keep-
ing the structure and adding all possible concepts and 
terms mappings to HPO, ICD, SNOMED CT, ORDO and 
NCIT. This way, in case an ISSVA term is not present in 
other existing ontologies, it has a unique identifier.
Setting up a registry requires a good balance between 
the amount of information one would like to collect, 
and the amount clinicians are able to provide given the 
limited time they can spend for each patient. In the 
current registry, clinicians provide all information. We 
are currently looking into the possibilities for a patient-
driven registry. In patient-driven registries, patients 
fill in (part of the) data themselves rather than the 
clinician. This way, we would be able to collect more 
data with less effort. This would additionally enhance 
the options for collecting longitudinal data (which is 
not covered by CDEs), for example on quality of life, 
medication intake or treatments, thereby allowing addi-
tional research questions to be answered.
In addition, reaching interoperability, and thereby 
facilitating secondary use of data from the EHR, 
requires the use of ontologies during data collection. 
Currently, this means that the data from the EHR (both 
structured fields and notes made by clinicians) should 
be ‘converted’ into terms used in the ontologies. This is 
currently mostly manual work and is heavily dependent 
on interpretation by the person carrying out the data 
entry in the EDC system. To further optimise and auto-
mate this process, we are currently exploring whether 
software tools that automatically map free text to 
ontologies can aid in this. An example implementation 
would be the facilitated mapping of diagnoses extracted 
from the EHR to HPO or other ontology terms, using 
software, such as Phenotips [38], Zooma [39], and 
SORTA [40, 41]. Alternatively, it would be interesting 
to work on a tool for mapping eCRF data with ontology 
terms.
The web-based query method in the EDC system can 
currently only be used to query data in one registry, 
but work is being done to support querying over mul-
tiple registries. This would allow for easier retrieval of 
relevant information from multiple registries. For fur-
ther interoperability, we would require an interface that 
facilitates queries over multiple registries, independ-
ent of the EDC system used for construction of the 
registries.
Next steps will also include the development of 
human and machine-readable access conditions to the 
data and, subsequently, the implementation of a mech-
anism for requesting and granting access to the data.
Conclusion
In conclusion, we successfully set up a workflow for 
de novo FAIRification of the CDEs for the registry of 
vascular anomalies. The methods and lessons learned 
in the different phases of the FAIRification process are 
described in detail (for methods see Additional file  1: 
Supplementary Methods). This may help other ERNs in 
setting up their FAIR registries.
Next steps are to extend the VASCA registry with 
disease-specific data elements and to set up this regis-
try in the other VASCA institutes and VASCERN work-
ing groups. This will allow us to analyse data across 
multiple registries using federated queries and, thereby, 
to demonstrate the added value of making them FAIR.
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Methods
Workflow of the de novo FAIRification process
The workflow of the de novo FAIRification process for 
the VASCA registry developed and implemented in this 
project is divided into five phases: (i) pre-FAIRification, 
(ii) facilitating FAIRification, (iii) data collection, (iv) gen-
erating FAIR data in real-time, and (v) using FAIR data 
(Fig. 1). The phases are further divided into steps describ-
ing practical FAIRification tasks detailed in Additional 
file 1.
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